Patents by Inventor William B. Parker

William B. Parker has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20180360929
    Abstract: The use of a purine nucleoside phosphorylase or nucleoside hydrolase or a vector encoding expression of one of these enzymes is detailed along with the use of a prodrug cleaved by the purine nucleoside phosphorylase or nucleoside hydrolase for the preparation of a direct injection inhibition of replicating or non-replicating targeted cells. The targeted cells do not normally express the introduced purine nucleoside phosphorylase or nucleoside hydrolase. The enzyme and prodrug are amenable to intermixing and injection as a single dose or as separate injection or administration to the targeted cells. The substance and prodrug efficacy are enhanced through exposure of the targeted cells to X-ray radiation. Administration of a prodrug regardless of administration route to the targeted cells is effective in combination with X-ray radiation therapy to kill or inhibit function of the targeted cells.
    Type: Application
    Filed: August 10, 2018
    Publication date: December 20, 2018
    Inventors: William B. Parker, Eric J. Sorscher
  • Patent number: 10080784
    Abstract: The use of a purine nucleoside phosphorylase or nucleoside hydrolase or a vector encoding expression of one of these enzymes is detailed along with the use of a prodrug cleaved by the purine nucleoside phosphorylase or nucleoside hydrolase for the preparation of a direct injection inhibition of replicating or non-replicating targeted cells. The targeted cells do not normally express the introduced purine nucleoside phosphorylase or nucleoside hydrolase. The enzyme and prodrug are amenable to intermixing and injection as a single dose or as separate injection or administration to the targeted cells. The substance and prodrug efficacy are enhanced through exposure of the targeted cells to X-ray radiation. Administration of a prodrug regardless of administration route to the targeted cells is effective in combination with X-ray radiation therapy to kill or inhibit function of the targeted cells.
    Type: Grant
    Filed: February 20, 2012
    Date of Patent: September 25, 2018
    Assignees: SOUTHERN RESEARCH INSTITUTE, THE UAB RESEARCH FOUNDATION
    Inventors: William B. Parker, Eric J. Sorscher
  • Publication number: 20160022784
    Abstract: A process for inhibiting a mammalian cancerous cell or virally infected cell includes providing a Trichomonas vaginalis purine nucleoside phosphorylase enzyme or a tail mutant purine nucleoside phosphorylase enzyme in proximity to the mammalian cancerous cell or the virally infected cell and exposing the enzyme to a purine nucleoside phosphorylase enzyme cleavable substrate to yield a cytotoxic purine analog. The process includes introducing to the cell a vector containing the phosphorylase enzyme, or a DNA sequence coding for the same and delivering to the cell an effective amount of the substrate such as 9-(?-D-arabinofuranosyl)-2-fluoroadenine (F-araA).
    Type: Application
    Filed: July 16, 2015
    Publication date: January 28, 2016
    Inventors: Steven E. EALICK, William B. PARKER, Eric J. SORSCHER
  • Publication number: 20140199285
    Abstract: A process for inhibiting a mammalian cancerous cell or virally infected cell includes providing a Trichomonas vaginalis purine nucleoside phosphorylase enzyme or a tail mutant purine nucleoside phosphorylase enzyme in proximity to the mammalian cancerous cell or the virally infected cell and exposing the enzyme to a purine nucleoside phosphorylase enzyme cleavable substrate to yield a cytotoxic purine analog. The process includes introducing to the cell a vector containing the phosphorylase enzyme, or a DNA sequence coding for the same and delivering to the cell an effective amount of the substrate such as 9-(?-D-arabinofuranosyl)-2-fluoroadenine (F-araA).
    Type: Application
    Filed: January 14, 2014
    Publication date: July 17, 2014
    Applicants: SOUTHERN RESEARCH INSTITUTE, THE UAB RESEARCH FOUNDATION
    Inventors: William B. Parker, Eric J. Sorscher
  • Patent number: 8628767
    Abstract: A process for inhibiting a mammalian cancerous cell or virally infected cell includes providing a Trichomonas vaginalis purine nucleoside phosphorylase enzyme or a tail mutant purine nucleoside phosphorylase enzyme in proximity to the mammalian cancerous cell or the virally infected cell and exposing the enzyme to a purine nucleoside phosphorylase enzyme cleavable substrate to yield a cytotoxic purine analog. The process includes introducing to the cell a vector containing the phosphorylase enzyme, or a DNA sequence coding for the same and delivering to the cell an effective amount of the substrate such as 9-(?-D-arabinofuranosyl)-2-fluoroadenine (F-araA).
    Type: Grant
    Filed: August 17, 2009
    Date of Patent: January 14, 2014
    Assignees: The UAB Research Foundation, Southern Research Institute
    Inventors: William B. Parker, Eric J. Sorscher
  • Publication number: 20130330315
    Abstract: The use of a purine nucleoside phosphorylase or nucleoside hydrolase or a vector encoding expression of one of these enzymes is detailed along with the use of a prodrug cleaved by the purine nucleoside phosphorylase or nucleoside hydrolase for the preparation of a direct injection inhibition of replicating or non-replicating targeted cells. The targeted cells do not normally express the introduced purine nucleoside phosphorylase or nucleoside hydrolase. The enzyme and prodrug are amenable to intermixing and injection as a single dose or as separate injection or administration to the targeted cells. The substance and prodrug efficacy are enhanced through exposure of the targeted cells to X-ray radiation. Administration of a prodrug regardless of administration route to the targeted cells is effective in combination with X-ray radiation therapy to kill or inhibit function of the targeted cells.
    Type: Application
    Filed: February 20, 2012
    Publication date: December 12, 2013
    Applicants: SOUTHERN RESEARCH INSTITUTE, THE UAB RESEARCH FOUNDATION
    Inventors: William B. Parker, Eric J. Sorscher
  • Publication number: 20110218170
    Abstract: Compounds represented by the formulae: wherein R is individually selected from the group consisting of H, aliphatic acyl, aromatic acyl group, fluoro, chloro, bromo, iodo, alkoxy, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, amino, monoalkylamino, dialkylamino, cyano, aryl and nitro; pharmaceutically acceptable salts thereof, prodrugs thereof, solvates thereof and mixtures thereof; are used as inhibitors of DNA methyltransferase and for treating patients suffering from diseases resulting from or related to aberrant DNA methylation such as myelodysplastic syndromes and other cancers.
    Type: Application
    Filed: March 2, 2010
    Publication date: September 8, 2011
    Applicant: Southern Research Institute
    Inventors: Jaideep Thottassery, Kamal N. Tiwari, William B. Parker, John A. Secrist, III
  • Publication number: 20110212073
    Abstract: A process for inhibiting a mammalian cancerous cell or virally infected cell includes providing a Trichomonas vaginalis purine nucleoside phosphorylase enzyme or a tail mutant purine nucleoside phosphorylase enzyme in proximity to the mammalian cancerous cell or the virally infected cell and exposing the enzyme to a purine nucleoside phosphorylase enzyme cleavable substrate to yield a cytotoxic purine analog. The process includes introducing to the cell a vector containing the phosphorylase enzyme, or a DNA sequence coding for the same and delivering to the cell an effective amount of the substrate such as 9-(?-D-arabinofuranosyl)-2-fluoroadenine (F-araA).
    Type: Application
    Filed: August 17, 2009
    Publication date: September 1, 2011
    Applicants: THE UAB RESEARCH FOUNDATION
    Inventors: William B. Parker, Eric J. Sorscher
  • Publication number: 20100151572
    Abstract: Described are methods and compositions for inhibiting undesired cells by expression of one or more exogenous enzymes in the cells and administration of a prodrug which is a substrate for at least one of the enzymes to produce a cytotoxic compound. Inventive methods and compositions are active to inhibit cells expressing the exogenous enzymes as well as bystander cells. Tumor cells are a particular target for inhibition using methods and compositions detailed according to the present invention. Provided are methods and compositions for improved anti-tumoral effects by overexpression of adenine phosphoribosyltransferase (APRT) to produce cytotoxins which inhibit the cells overexpressing the APRT as well as bystander cells. Overexpression of APRT in conjunction with expression of E. coli PNP and administration of a substrate for E. coli PNP provides particularly effective anti-tumoral effects.
    Type: Application
    Filed: May 16, 2006
    Publication date: June 17, 2010
    Inventors: Eric J. Sorscher, William B. Parker, Jeong S. Hong
  • Publication number: 20100129317
    Abstract: Azole nucleosides represented by the formulae (I) and (II); wherein A=C or N B?C or N X?H; C1-C6 alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, heterocyclo, halogen such as F, Cl, Br and I; OH, NH2, NH—(C1-C6 alkyl, cycloalkyl, aryl or heterocyclo); Z?H; C1-C6 alkyl, cycloalkyl, alkynyl, aryl, heterocyclo, halogen such as F, Cl, Br, I; OH NH2, NH—(C1-C6 alkyl, cycloalkyl, aryl or heterocyclo; E=(CH2)HONHR; n is an interger from 0-6 and more typically 0-3; R1= aryl or heterocyclo; each of W, Y, R is individually selected from the group consisting of H; C1-C6 alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, heterocyclo, halogen such as F, Cl, Br, and I; O, OH, Oalkyl, Oaryl, NH2, NH(C1-C6 alkyl, cycloalkyl, aryl or heterocyclo); provided that at least one of W, Y, and R is other than H and wherein both W and Y together can be ?O; and each D individually is OH, Oalkyl, Oaryl, FL and H; pharmaceutically acceptable salts thereof, prodrugs thereof and mixtures thereof are provided.
    Type: Application
    Filed: September 11, 2007
    Publication date: May 27, 2010
    Applicant: SOUTHERN RESEARCH INSTITUTE
    Inventors: Jeffrey B. Arterburn, Colleen B. Jonsson, William B. Parker
  • Patent number: 7488598
    Abstract: A host cell stably transformed or transfected by a vector including a DNA sequence encoding for mutant purine nucleoside cleavage enzymes is provided. The transformed or transfected host cell can be used in combination with a purine substrate to treat tumor cells and/or virally infected cells. A nucleotide sequence encoding mutant E. coli derived purine nucleoside phosphorylase proteins which can be used in conjunction with an appropriate substrate to produce toxins which impair abnormal cell growth is also provided. A method is detailed for the delivery of toxin by generation within target cells or by administration and delivery to the cells from without. Novel purine nucleosides are detailed that yield a cytotoxic purine upon enzymatic cleavage. A synthetic process for nucleosides is also detailed.
    Type: Grant
    Filed: October 28, 2002
    Date of Patent: February 10, 2009
    Assignees: Cornell Center for Technology Enterprise and Commercialization, The UAB Research Foundation, Southern Research Institute
    Inventors: Steven E. Ealick, William B. Parker, John A. Secrist, III, Eric J. Sorscher
  • Patent number: 7048079
    Abstract: A three-part sub-assembly comprising a wire line retrievable spear. The spear having two fluid chambers. A diverter valve having a truncated, inverted cone valve seat is preferably threaded into the interior of the spear. A diverter valve stem, having back-to-back cones is located within the interior of the spear/diverter valve combination, with one of the cones having a linear extension which prevents the first cone from completely seating against the valve seat within the interior of the spear. The spear/diverter valve assembly and a spring-loaded piston is placed within the interior of the cylinder and utilizes an adjustable ring within the interior of the cylinder as an adjustment for varying mud weights.
    Type: Grant
    Filed: July 11, 2002
    Date of Patent: May 23, 2006
    Assignee: Mud Saver, Inc.
    Inventor: William B. Parker
  • Patent number: 7037718
    Abstract: The present invention provides a procaryotic host cell stably transformed or transfected by a vector including a DNA sequence encoding for mutant purine nucleoside phosphorylase or hydrolase. The transformed or transfected procaryotic host cell can be used in combination with a purine substrate to treat tumor cells and/or virally infected cells. The present invention provides nucleotide sequences encoding mutant E. coli derived purine nucleoside phosphorylase proteins which can be used in conjunction with an appropriate substrate to produce toxins which impair abnormal cell growth. The invention provides for delivery of the toxin by generation within target cells or by administration and delivery to the cells from without.
    Type: Grant
    Filed: October 26, 2001
    Date of Patent: May 2, 2006
    Assignees: Cornell Research Foundation, Inc., Southern Research Institute, The UAB Research Foundation
    Inventors: Steven E. Ealick, William B. Parker, John A. Secrist, III, Eric J. Sorscher
  • Patent number: 6958318
    Abstract: The present invention provides a procaryotic host cell stably transformed or transfected by a vector including a DNA sequence encoding for purine nucleoside phosphorylase or hydrolase. The transformed or transfected procaryotic host cell can be used in combination with a purine substrate to treat tumor cells and/or virally infected cells.
    Type: Grant
    Filed: July 18, 2002
    Date of Patent: October 25, 2005
    Assignees: The UAB Research Foundation, Southern Research Institute
    Inventors: Eric J. Sorscher, William B. Parker, William Waud, Vijayakrishna K. Gadi, Leonard L. Bennett, Jr.
  • Publication number: 20040204375
    Abstract: Compounds having the structure: 1
    Type: Application
    Filed: November 3, 2003
    Publication date: October 14, 2004
    Inventors: Eric J Sorscher, Jeong S Hong, Jennifer E Harris, Kimberly V Curlee, Joseph A Maddry, William B Parker, William R Wand
  • Publication number: 20030228576
    Abstract: The present invention provides a procaryotic host cell stably transformed or transfected by a vector including a DNA sequence encoding for mutant purine nucleoside phosphorylase or hydrolase. The transformed or transfected procaryotic host cell can be used in combination with a purine substrate to treat tumor cells and/or virally infected cells. The present invention provides nucleotide sequences encoding mutant E. coli derived purine nucleoside phosphorylase proteins which can be used in conjunction with an appropriate substrate to produce toxins which impair abnormal cell growth. The invention provides for delivery of the toxin by generation within target cells or by administration and delivery to the cells from without.
    Type: Application
    Filed: October 26, 2001
    Publication date: December 11, 2003
    Inventors: Steven E. Ealick, William B. Parker, John A. Secrist, Eric J. Sorscher
  • Publication number: 20030134819
    Abstract: The present invention provides a procaryotic host cell stably transformed or transfected by a vector including a DNA sequence encoding for purine nucleoside phosphorylase or hydrolase. The transformed or transfected procaryotic host cell can be used in combination with a purine substrate to treat tumor cells and/or virally infected cells.
    Type: Application
    Filed: July 18, 2002
    Publication date: July 17, 2003
    Inventors: Eric J. Sorscher, William B. Parker, William Waud, Vijayakrishna K. Gadi, Leonard L. Bennett
  • Publication number: 20030077268
    Abstract: The present invention provides a procaryotic host cell stably transformed or transfected by a vector including a DNA sequence encoding for purine nucleoside phosphorylase or hydrolase. The transformed or transfected procaryotic host cell can be used in combination with a purine substrate to treat tumor cells and/or virally infected cells.
    Type: Application
    Filed: July 18, 2002
    Publication date: April 24, 2003
    Inventors: Eric J. Sorscher, William B. Parker, William Waud, Vijayakrishna K. Gadi, Leonard L. Bennett
  • Patent number: 6491905
    Abstract: The present invention provides a procaryotic host cell stably transformed or transfected by a vector including a DNA sequence encoding for purine nucleoside phosphorylase or hydrolase. The transformed or transfected procaryotic host cell can be used in combination with a purine substrate to treat tumor cells and/or virally infected cells.
    Type: Grant
    Filed: October 30, 1998
    Date of Patent: December 10, 2002
    Assignees: The UAB Research Foundation, Southern Research Institute
    Inventors: Eric J. Sorscher, William B. Parker, William Waud, Vijayakrishna K. Gadi, Leonard L. Bennett, Jr.
  • Patent number: 6414222
    Abstract: The present invention provides methods for preparing herbicide tolerant corn plants. Also provided are herbicide tolerant corn plants, as well as seeds and progeny derived from these plants.
    Type: Grant
    Filed: August 30, 1996
    Date of Patent: July 2, 2002
    Assignee: Regents of the University of Minnesota
    Inventors: Burle G. Gengenbach, David A. Somers, Margaret A. Egli, Lorelei C. Marshall, Donald L. Wyse, Shelia M. Lutz, Kevin L. Van Dee, William B. Parker